Daily angina documentation versus subsequent recall: development of a symptom smartphone app

Author:

Nowbar Alexandra N12ORCID,Howard James P12,Shun-Shin Matthew J12,Rajkumar Christopher12,Foley Michael12ORCID,Basu Arunima1,Goel Akshit1,Patel Sapna1,Adnan Ahmer1,Beattie Catherine J1,Keeble Thomas R34,Sohaib Afzal5,Collier David6,McVeigh Patrick1,Harrell Frank E7,Francis Darrel P12,Al-Lamee Rasha K12

Affiliation:

1. National Heart and Lung Institute, Imperial College London , London W12 0HS , UK

2. Imperial College Healthcare NHS Trust, Hammersmith Hospital , London W12 0HS , UK

3. Essex Cardiothoracic Centre, MSE Trust , Basildon, Essex , UK

4. MTRC, Anglia Ruskin School of Medicine , Chelmsford, Essex , UK

5. Barts Heart Centre, Barts Health NHS Trust , W Smithfield, London EC1A 7BE , UK

6. William Harvey Research Institute, Queen Mary University of London , London , UK

7. Department of Biostatistics, Vanderbilt University School of Medicine , Nashville, TN , USA

Abstract

Abstract Aims The traditional approach to documenting angina outcomes in clinical trials is to ask the patient to recall their symptoms at the end of a month. With the ubiquitous availability of smartphones and tablets, daily contemporaneous documentation might be possible. Methods and results The ORBITA-2 symptom smartphone app was developed with a user-centred iterative design and testing cycle involving a focus group of previous ORBITA participants. The feasibility and acceptability were assessed in an internal pilot of participants in the ongoing ORBITA-2 trial. Seven days of app entries by ORBITA-2 participants were compared with subsequent participant recall at the end of the 7-day period. The design focus group tested a prototype app. They reported that the final version captured their symptoms and was easy to use. In the completion assessment group, 141 of 142 (99%) completed the app in full and 47 of 141 (33%) without reminders. In the recall assessment group, 29 of 29 (100%) participants said they could recall the previous day’s symptoms, and 82% of them recalled correctly. For 2 days previously, 88% said they could recall and of those, 87% recalled correctly. The proportion saying they could recall their symptoms fell progressively thereafter: 89, 67, 61, 50%, and at 7 days, 55% (P < 0.001 for trend). The proportion of recalling correctly also fell progressively to 55% at 7 days (P = 0.04 for trend). Conclusion Episode counts of angina are difficult to recall after a few days. For trials such as ORBITA-2 focusing on angina, daily symptom collection via a smartphone app will increase the validity of the results.

Publisher

Oxford University Press (OUP)

Subject

Energy Engineering and Power Technology,Fuel Technology

Reference12 articles.

1. Optimal medical therapy with or without PCI for stable coronary disease;Boden;N Engl J Med,2007

2. Initial invasive or conservative strategy for stable coronary disease;Maron;N Engl J Med,2020

3. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease;Spertus;J Am Coll Cardiol,1995

4. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial;Al-Lamee;Lancet Lond Engl,2018

5. A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina - full text view - ClinicalTrials.gov [Internet]

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3